Enlivex Therapeutics Ltd (ENLV) Stock Price, Quote & News

Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 2 620 8072

Website: www.enlivex.com

Address:

14 Einstein Street, Ness Ziona, Israel

Pharaon_Cr Aug. 7 at 11:09 PM

$ENLV I mean DIOR but they say it on their website @mbelect.... https://enlivex.com/investors/news-releases/enlivex-reaffirms-august-18-2025-as-target-date-for-announcement-of-phase-ii-topline-data/

0 · Reply

Pharaon_Cr Aug. 7 at 11:04 PM

🚀 $ENLV is on track for a major breakout! Phase II knee osteoarthritis results coming August 18, 2025 — targeting a massive $200+ billion market with no current disease-modifying treatments. 📈 Key stats & insights from sources like BioPharmCatalyst, Seeking Alpha, and Stocktwits: Current price: ~$1.48 Market cap: $ 32M — perfect mid-cap spotlight Analyst price targets: $ 10 – $ 13, implying a potential 640%-780% upside (Seeking Alpha, Zacks) Strong technical momentum: Price above 50/200-day MAs, RSI near 79 ! Phase I/II trial showed 47% pain reduction & better joint function — huge for patients & valuation! Enlivex’s unique cell therapy reprograms the immune system to heal naturally, with broad potential beyond osteoarthritis, including inflammatory diseases. With increasing retail interest and “Strong Buy” analyst ratings, this could be one of 2025’s hottest biotech stories! 🔥 Mark your calendar 👉 August 18. Don’t miss the run-up! $BTAI $TNXP $CERO $CADL

1 · Reply

squiggleburp Aug. 7 at 8:44 PM

$ENLV You sure? Enlivex has officially reaffirmed that audited topline results will be announced on August 18, 2025—covering the 3-month key endpoints for both safety and efficacy.

0 · Reply

mbelect Aug. 7 at 8:09 PM

$ENLV not a lot of confidence in any news coming

0 · Reply

JuniperLuna Aug. 7 at 2:55 PM

$HUMA I got distracted by $BTAI and $ENLV, what's going on over here??????

0 · Reply

squiggleburp Aug. 7 at 1:52 PM

$EDGM $ENLV $IXHL $VERB EDGM- there go those Spidey Senses. Financing news? Drop kick me Jesus!

0 · Reply

RbNueve Aug. 7 at 5:32 AM

Didn’t touch my wife for a month now, there is only $ENLV who makes me hard & #bullish

0 · Reply

maxstk Aug. 6 at 9:28 PM

$ENLV Just Buying Enlivex She’s not just wearing a shirt, she’s wearing hope. After decades with no real innovation, millions living with life-threatening inflammation still wait. Enlivex isn’t just another biotech, it’s pioneering Allocetra™, a therapy designed to rebalance the immune system in critical conditions like sepsis and beyond. The science is real. The data is strong. The need is urgent. The market isn’t ready. But it will be 👀 $IXHL $BTAI $REPL $UNCY

1 · Reply

Bikinix Aug. 6 at 8:53 PM

$ENLV has been consolidating for around a year now and has a strong catalyst to come on the 18th of August. I can definitely see a breakout above 1.6$ in the upcoming days, prior to the 18th of August. With good momentum and good news, the company could reach a resistance 2 at 3$. Midterm, retesting the 4.4$ level could be totally feasible as well. Extremely bullish at this price with easy gain opportunity of at least 20% - 100% short term. Enjoy the ride !!!

0 · Reply

maxstk Aug. 6 at 8:46 PM

$ENLV don’t click on watchlist or bullish button. Buy the dip, I’m not talking about hype but solid data. 📈 I’m extremely bullish and just buying couple more share. Look $BTAI or $ZEPP That’s exactly the same! Future you will high five you..

0 · Reply

Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data

Jun 10, 2025, 8:30 AM EDT - 2 months ago

Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology

May 20, 2025, 8:00 AM EDT - 2 months ago

Enlivex Selected to Present at Israeli BioMed 2025 Conference

Apr 23, 2025, 8:30 AM EDT - 3 months ago

Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress

Apr 21, 2025, 8:30 AM EDT - 3 months ago

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

Apr 3, 2025, 8:00 AM EDT - 4 months ago

Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Mar 17, 2025, 8:00 AM EDT - 5 months ago

Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Mar 4, 2025, 4:30 PM EST - 5 months ago

Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis

Mar 3, 2025, 8:22 AM EST - 5 months ago

Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis

Feb 18, 2025, 6:20 AM EST - 6 months ago

Enlivex Issues Urgent Statement on Fraudulent News Dissemination

Jan 10, 2025, 9:00 AM EST - 7 months ago

Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BIAF

Dec 11, 2024, 8:30 AM EST - 8 months ago

Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Dec 5, 2024, 10:49 AM EST - 8 months ago

Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

Nov 26, 2024, 10:15 AM EST - 9 months ago

Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3

Nov 14, 2024, 8:00 AM EST - 9 months ago

Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis

Oct 30, 2024, 8:00 AM EDT - 10 months ago

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis

Sep 24, 2024, 8:30 AM EDT - 11 months ago

Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Aug 30, 2024, 9:00 AM EDT - 1 year ago

GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jul 19, 2024, 9:00 AM EDT - 1 year ago

Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jun 17, 2024, 8:00 AM EDT - 1 year ago

Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis

May 29, 2024, 4:15 PM EDT - 1 year ago

Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering

May 28, 2024, 8:12 AM EDT - 1 year ago

Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering

Apr 16, 2024, 7:50 AM EDT - 1 year ago

Enlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

Apr 11, 2024, 2:58 PM EDT - 1 year ago

Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis

Apr 11, 2024, 8:05 AM EDT - 1 year ago

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis

Mar 22, 2024, 10:50 AM EDT - 1 year ago

Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

UMAC

Feb 26, 2024, 8:30 AM EST - 1 year ago

Enlivex Receives Regulatory Authorization From Israel's Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis

Feb 21, 2024, 8:30 AM EST - 1 year ago

Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals

Jan 17, 2024, 8:00 AM EST - 1 year ago

Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis

Dec 20, 2023, 8:00 AM EST - 1 year ago

Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis

Jul 31, 2023, 8:00 AM EDT - 2 years ago

Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis

Jun 6, 2023, 8:00 AM EDT - 2 years ago

Enlivex to Present at the 2023 Jefferies Healthcare Conference

May 31, 2023, 8:04 AM EDT - 2 years ago

Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy

May 8, 2023, 8:00 AM EDT - 2 years ago

Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy

Apr 19, 2023, 8:00 AM EDT - 2 years ago

Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy

Apr 17, 2023, 8:00 AM EDT - 2 years ago

Enlivex Appoints Andrew Singer to its Board of Directors

Apr 14, 2023, 9:40 AM EDT - 2 years ago

Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials

Apr 12, 2023, 10:45 AM EDT - 2 years ago

Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors

Apr 4, 2023, 8:00 AM EDT - 2 years ago

Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates

Apr 3, 2023, 8:00 AM EDT - 2 years ago

Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors

Mar 20, 2023, 8:00 AM EDT - 2 years ago

Enlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers

Feb 15, 2023, 8:00 AM EST - 2 years ago

Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS

Jan 25, 2023, 8:37 AM EST - 2 years ago

Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors

Dec 5, 2022, 8:00 AM EST - 2 years ago

Enlivex Announces Third Quarter 2022 Financial Results and Provides a Business Update

Nov 15, 2022, 8:00 AM EST - 2 years ago

Enlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

Oct 3, 2022, 8:13 AM EDT - 3 years ago

Enlivex to Present at the 4th Macrophage-Directed Therapies Summit

Sep 30, 2022, 2:08 AM EDT - 3 years ago

Enlivex Therapeutics: A Very Enticing Early-Stage Biotech

Sep 13, 2022, 8:00 AM EDT - 3 years ago

Enlivex to Present at Upcoming Investor and Media Conferences

Sep 12, 2022, 8:00 AM EDT - 3 years ago

Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022

Aug 29, 2022, 8:00 AM EDT - 3 years ago

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells

Pharaon_Cr Aug. 7 at 11:09 PM

$ENLV I mean DIOR but they say it on their website @mbelect.... https://enlivex.com/investors/news-releases/enlivex-reaffirms-august-18-2025-as-target-date-for-announcement-of-phase-ii-topline-data/

0 · Reply

Pharaon_Cr Aug. 7 at 11:04 PM

1 · Reply

squiggleburp Aug. 7 at 8:44 PM

$ENLV You sure? Enlivex has officially reaffirmed that audited topline results will be announced on August 18, 2025—covering the 3-month key endpoints for both safety and efficacy.

0 · Reply

mbelect Aug. 7 at 8:09 PM

$ENLV not a lot of confidence in any news coming

0 · Reply

JuniperLuna Aug. 7 at 2:55 PM

$HUMA I got distracted by $BTAI and $ENLV, what's going on over here??????

0 · Reply

squiggleburp Aug. 7 at 1:52 PM

$EDGM $ENLV $IXHL $VERB EDGM- there go those Spidey Senses. Financing news? Drop kick me Jesus!

0 · Reply

RbNueve Aug. 7 at 5:32 AM

Didn’t touch my wife for a month now, there is only $ENLV who makes me hard & #bullish

0 · Reply

maxstk Aug. 6 at 9:28 PM

1 · Reply

Bikinix Aug. 6 at 8:53 PM

0 · Reply

maxstk Aug. 6 at 8:46 PM

0 · Reply

JuniperLuna Aug. 6 at 8:04 PM

$ENLV I’m getting in this for the sepsis indication $$$$$$

0 · Reply

squiggleburp Aug. 6 at 8:03 PM

$ENLV Why is the market missing this? This upcoming data read is quite important for the company so regardless, the stock should move. It looks like there is minimal option interest as well. I have a secret for you all, if there is anyone out there. If this stock runs and you have the capital there may be an opportunity to sell some calls (yes naked, I know, I am a bad boy) on a spike, If vol expands? We shall see- I have been known to gobble up free premium. BURP!

3 · Reply

maxstk Aug. 6 at 7:55 PM

$ENLV The biotech sleeper nobody’s watching… but it’s about to drop a Phase 2 knee bomb on August 18. 🚀 🦵 Target : knee osteoarthritis (aka “everyone over 40” disease) 📉 Market cap : $33M, smaller than a gas station chain 📦 Float : dryer than the Sahara 📊 Hype level : 0 💣 Risk/reward ratio : chaos-in-the-making 🧬 If the data hits, forget $1.30, we’re not talking pop, we’re talking catapult. 🔥 Add a sprinkle of short covering and you’ve got yourself a biotech bonfire. While everyone’s chasing the next AI coin flip, or $IXHL $BTAI $ZEPP this thing is loading a real human trial readout… with actual science. Not a pump. A fuse. Because when this goes off… your grandma won’t just feel better, she’ll be breakdancing in Skechers. Just buying the dip 🚀🚀

3 · Reply

Pharaon_Cr Aug. 6 at 7:52 PM

$SMCI this is a joke… soo much volatility… I prefer to deal with early stage biotech like $ENLV $BTAI or $TNXP at least I know with what I am dealing with…

0 · Reply

Jeanvaljean4 Aug. 6 at 7:44 PM

The Company That Could Help Grandma Walk Like She’s 40 Again $ETH.X $IXHL $NVOX.X $TNXP $ENLV is trading at a market cap of just ~$33M, despite an imminent catalyst: Phase II results for Allocetra™ in knee osteoarthritis, expected on August 18, 2025. If efficacy is confirmed, the valuation could triple as the market re-rates its addressable base of over 300 million patients with no curative treatment.

1 · Reply

RbNueve Aug. 6 at 7:43 PM

My mother has just died... 😢 but the inheritance gives me cash flow for $ENLV 🤠🤠🤠🤠🤠

0 · Reply

Pharaon_Cr Aug. 6 at 7:34 PM

Missed ou on $BTAI ? Take a look at $ENLV , right now it is at a stealth levels with a small MC (30M) and very low volume, but with a major trials catalyst approaching, this is exactly where rally can start. $BTAI run began with similar fundamentals and $ENLV could be next a smart money under the radar biotech. I did personally TP and rotate, early entry is open ! Don’t wait for the crowd and buy $ENLV ! 🦬

0 · Reply

maxstk Aug. 6 at 7:12 PM

$BTAI $ENLV totally agree 👍 Let’s take a look with Envilex, major data will release 18 of August. That’s massive. Strong buy

0 · Reply

RbNueve Aug. 6 at 6:46 PM

$BTAI extremely bullish as expected… Can’t wait for his big brother $ENLV

0 · Reply

Duuri Aug. 6 at 6:28 PM

$ENLV really liking this setup

0 · Reply

counter Aug. 6 at 5:40 PM

$ENLV why is there such limited interest with data coming

1 · Reply

maxstk Aug. 6 at 5:06 PM

$ENLV just buying the dip. The data reveal will be amazing. Don’t sleep guys, that’s an amazing price

0 · Reply

Market Cap	31.93M
Revenue (ttm)	0.00
Net Income (ttm)	-15.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	203,700
Avg Vol	181,258
Day's Range	N/A - N/A
Shares Out	23.65M
Stochastic %K	38%
Beta	0.80
Analysts	Strong Sell
Price Target	$10.00